438049-35-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.438049-35-5,N-Boc-3-Ethylpiperazine,as a common compound, the synthetic route is as follows.
Anhydrous DMF solution N’N- carbonyl diimidazole (468mg, 2.80mmol) of (2mL) was added dropwisetriethylamine (0.59mL, 4.20 mmol) and N- tert-butoxycarbonyl-3-ethylpiperazine (500mg, 2.33mmol) inanhydrous DMF (2mL) solution at room temperature in a sealed tube 30min, adding anhydrous methanol(12mL), 60 C the reaction 24h, the solvent was removed, a saturated sodium chloride solution (30 mL), ethyl acetate (15mL ¡Á 2) and the combined organic phases, Na 2 SO 4 dried over anhydrous solvent removedconcentrate was subjected to column chromatography (eluent: Petroleum ether / EtOAc (v / v) = 5/1), to give260mg of colorless liquid: 4-tert-butoxycarbonyl-2-ethyl-piperazine-1-carboxylate, yield: 40%.
As the paragraph descriping shows that 438049-35-5 is playing an increasingly important role.
Reference£º
Patent; Guangdong East Sunshine Pharmaceutical Co., Ltd; Zhang, Ying jun; Liu, Bing; Yu, Tian Zhu; Zhang, Xiang Yu; (348 pag.)CN105399698; (2016); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics